Increase in Ischemia-Modified Albumin and Pregnancy-Associated Plasma Protein-A in COVID-19 Patients

Sánchez, Belén G.; Gasalla, Jose M.; Sánchez‐Chapado, Manuel; Bort, Alicia; Díaz‐Laviada, Inés

doi:10.3390/jcm10235474

Cited by 7 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PAPP-A is a protein that is under the regulation of pro-inflammatory cytokines including IL-1 β and TNF- α [ 23 ]. A recent retrospective study of COVID-19 demonstrated elevated serum levels of PAPP-A protein in early infected patients and suggested PAPP-A as a biomarker to the early stage of COVID-19 [ 24 ]. SARS-CoV-2 study in pregnant patients and control group demonstrated no differences of PAPP-A gene expression between cohorts [ 25 ].…”

Section: Resultsmentioning

confidence: 99%

Preliminary investigation of gene expression levels of PAPP-A, STC-2, and HIF-1α in SARS-Cov-2 infected patients

et al. 2022

View full text Add to dashboard Cite

Background Coronavirus-19 is still considered a pandemic that influences the world. Other molecular alterations should be clearer besides the increasing cytokine storm and pro-inflammatory molecules. Hypoxic conditions that induce HIF-1α lead to stimulate gene expression of STC-2 that targets PAPP-A expression. This study aimed to determine gene expression levels of PAPP-A, STC-2, and HIF-1α in COVID-19 infection. We also aimed to reveal the relationship of these genes with laboratory and clinical data of COVID-19 patients. Materials and Results We extracted RNA from peripheral blood samples of COVID-19(+) and COVID-19(−) individuals. The real-time PCR method was used to measure mRNA expression of PAPP-A, STC-2, and HIF-1α. Gene expression analysis was evaluated by the 2 −ΔΔCt method. PAPP-A, STC-2, and HIF-1α mRNA expressions of severe patients were higher than healthy individuals ( p = 0.0451 , p = 0.4466 , p < 0.0001, respectively). Correlation analysis of gene expression patterns of severe patients demonstrated a positive correlation between PAPP-A and STC-2 ( p < 0.0001 , r = 0.8638). Conclusion This is the first study that investigates the relation of PAPP-A, STC-2, and HIF-1α gene expression in patients with COVID-19 infection. Besides the routine laboratory findings, PAPP-A, STC-2, and HIF-1α mRNA expressions may be considered to patients’ prognosis as a sign of increased cytokines and pro-inflammatory molecules.

show abstract

Section: Resultsmentioning

confidence: 99%

Preliminary investigation of gene expression levels of PAPP-A, STC-2, and HIF-1α in SARS-Cov-2 infected patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In another study, it was stated that IMA levels were higher in the early phase of COVID-19 than in the acute phase [ 11 ]. One of the limitations of our study is that the days of the COVID-19 patients were not included.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Serum Ischemia Modified Albumin in Patients With COVID-19 Pneumonia: A Case-Control Study

Altıntaş¹,

Sabırlı²,

Yuksekkaya³

et al. 2022

Cureus

View full text Add to dashboard Cite

Introduction: Various biomarkers are used when evaluating the hospitalization needs of patients diagnosed with Coronavirus disease (COVID-19). Ischemia-modified albumin (IMA) is a biomarker that causes blood levels to increase as a result of hypoxia and acidosis. We think that an increase in IMA in the blood may be caused by hypoxia stemming from lung damage. This study aimed to compare the mean/median of the blood IMA value in patients with pneumonia due to COVID-19 infection with a control group. Methods: The case group included patients with COVID-19 pneumonia detected by lung imaging and a positive COVID test. Demographic information of the case group, the severity of pneumonia, and their PCR test results were recorded in the data set.Findings: A total of 150 people, 90 of whom were in the case group and 60 of whom were in the control group, participated in the study. No statistically significant differences were found between the blood IMA levels of the case group and the control group. When the blood IMA levels of the case group were compared according to pneumonia severity, no statistically significant differences were found between the mild-moderate and severe pneumonia groups.Conclusion: Blood IMA levels are not a diagnostic biomarker for patients with COVID-19 pneumonia and are not helpful in predicting the severity of pneumonia.

show abstract

“…Ischemia-modified albumin (IMA), a type of human serum albumin, where N-terminal amino acids cannot bind transition metals, is a highly sensitive marker for hypoxia [ 12 ]. Because of the absence of dyspnea and the extremely low oxygen saturation (sO 2 ) level (silent hypoxia) in COVID-19 patients, these patients are at extremely high risk, and the underlying pathomechanism is still unclear [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

“…Because of the absence of dyspnea and the extremely low oxygen saturation (sO 2 ) level (silent hypoxia) in COVID-19 patients, these patients are at extremely high risk, and the underlying pathomechanism is still unclear [ 13 ]. Sanchez et al observed a significant increase in IMA levels in the early period in 84 patients infected with COVID-19 [ 12 ]. This study suggests that serum IMA levels can be taken as an effective new biomarker with high sensitivity for the initial phase of COVID-19 [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

Gökmen

Şener

Bayrak

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is a systemic disease which causes an increased inclination to thrombosis by leading to coagulation system activation and endothelial dysfunction. Our objective in this study is to determine whether ischemia-modified albumin (IMA) can be used as a new marker in patients with COVID-19 for evaluating the increased coagulation risk, pneumonic infiltration, and thus, prognosis. Methods: Our study included 59 patients with COVID-19 compatible pneumonic infiltration on lung computed tomography (CT) who applied to and were hospitalized in the Internal Diseases Outpatient Clinic, then followed up and treated, as well as 29 healthy individuals with a negative COVID-19 rRT-PCR test without any additional disease. Hemogram, coagulation, routine biochemistry, and serum IMA activity parameters were studied. Results: In our study, the higher serum IMA level in COVID-19 patients with pneumonic infiltration compared to that of the healthy control group was found to be statistically significant. No significant correlation was found between the serum IMA levels and the coagulation and inflammation parameters in the 59 COVID-19 patients included. Conclusions: Serum IMA levels in COVID-19 patients with pneumonic infiltration on CT were found to be higher than in the control group. Examination of biochemical parameters, especially thrombotic parameters that affect prognosis such as IMA, can be a guide in estimating pneumonic infiltration.

show abstract

Increase in Ischemia-Modified Albumin and Pregnancy-Associated Plasma Protein-A in COVID-19 Patients

Cited by 7 publications

References 41 publications

Preliminary investigation of gene expression levels of PAPP-A, STC-2, and HIF-1α in SARS-Cov-2 infected patients

Preliminary investigation of gene expression levels of PAPP-A, STC-2, and HIF-1α in SARS-Cov-2 infected patients

Evaluation of Serum Ischemia Modified Albumin in Patients With COVID-19 Pneumonia: A Case-Control Study

Analysis of Ischemia-Modified Albumin (IMA) and Coagulation Parameters in Patients with SARS-CoV-2 Pneumonia

Contact Info

Product

Resources

About